Literature DB >> 20167173

Compatibility of insulin Lispro, Aspart, and Glulisine with the Solo MicroPump, a novel miniature insulin pump.

Gil Senesh1, Doron Bushi, Avraham Neta, Ofer Yodfat.   

Abstract

BACKGROUND: This study compared the stability of commercially available, rapid-acting insulin in the novel tubeless, skin-adhering Solo insulin pump over 6 days at extreme environmental conditions.
METHODS: Forty-eight pumps for each tested analog were loaded with three different insulin lots and operated at 30 U/day (three sets of 12 pumps) and 15 U/day (one set of 12 pumps) with basal/bolus delivery patterns for 6 days under extreme climatic (37 degrees C, 40% relative humidity) and mechanical (35 strokes/min) stresses. The insulin solutions dispensed were sampled periodically and analyzed for potency, related substances, high molecular weight proteins (HMWP), and preservative content by high-performance liquid chromatography techniques. Biological activity (bioidentity) was demonstrated by an abrupt decrease in blood glucose in rabbits. Solutions were inspected for visual appearance and measured for pH levels.
RESULTS: During the 6-day sampling period, the potency of all insulin samples was maintained at 95.0-105.0% of the bulk solution concentration of the insulin vials. The levels of HMWP and related substances remained well below labeling limits. The preservative concentration decreased with time but remained bacteriostatic effective. Solutions maintained pH and clarity and were particulate free. The biological activity was verified.
CONCLUSIONS: Insulin analogs lispro, aspart, and glulisine maintained physical, chemical, and biological properties for 6 days when used in the Solo MicroPump device. 2010 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167173      PMCID: PMC2825630          DOI: 10.1177/193229681000400113

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  9 in total

Review 1.  Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy.

Authors:  M J Lenhard; G D Reeves
Journal:  Arch Intern Med       Date:  2001-10-22

2.  Precipitation of insulin products used for continuous subcutaneous insulin infusion.

Authors:  Christian Poulsen; Lotte Langkjaer; Carsten Worsøe
Journal:  Diabetes Technol Ther       Date:  2005-02       Impact factor: 6.118

3.  Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces.

Authors:  V Sluzky; J A Tamada; A M Klibanov; R Langer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

4.  In vitro stability of insulin lispro in continuous subcutaneous insulin infusion.

Authors:  Michael R DeFelippis; Maureen A Bell; Jennifer A Heyob; Sacha M Storms
Journal:  Diabetes Technol Ther       Date:  2006-06       Impact factor: 6.118

Review 5.  Toward understanding insulin fibrillation.

Authors:  J Brange; L Andersen; E D Laursen; G Meyn; E Rasmussen
Journal:  J Pharm Sci       Date:  1997-05       Impact factor: 3.534

6.  Effect of contact material on vibration-induced insulin aggregation.

Authors:  V Feingold; A B Jenkins; E W Kraegen
Journal:  Diabetologia       Date:  1984-09       Impact factor: 10.122

Review 7.  Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy.

Authors:  Daniela Bruttomesso; Silvana Costa; Aldo Baritussio
Journal:  Diabetes Metab Res Rev       Date:  2009-02       Impact factor: 4.876

8.  Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps.

Authors:  Jakob Senstius; Christian Poulsen; Aage Hvass
Journal:  Diabetes Technol Ther       Date:  2007-12       Impact factor: 6.118

9.  Insulin pumps and insulin quality--requirements and problems.

Authors:  J Brange; S Havelund
Journal:  Acta Med Scand Suppl       Date:  1983
  9 in total
  5 in total

Review 1.  Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: a systematic review.

Authors:  David Kerr; Erik Wizemann; Jakob Senstius; Mette Zacho; Francisco Javier Ampudia-Blasco
Journal:  J Diabetes Sci Technol       Date:  2013-11-01

2.  Characterizing normal-use temperature conditions of pumped insulin.

Authors:  Joshua K Herr; Steven Keith; Rick Klug; Ronald J Pettis
Journal:  J Diabetes Sci Technol       Date:  2014-05-12

Review 3.  A review of the security of insulin pump infusion systems.

Authors:  Nathanael Paul; Tadayoshi Kohno; David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

4.  Phenolic Preservative Removal from Commercial Insulin Formulations Reduces Tissue Inflammation while Maintaining Euglycemia.

Authors:  Adam Mulka; Brianne E Lewis; Li Mao; Roshanak Sharafieh; Shereen Kesserwan; Rong Wu; Donald L Kreutzer; Ulrike Klueh
Journal:  ACS Pharmacol Transl Sci       Date:  2021-04-26

Review 5.  Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience.

Authors:  Kjeld Hermansen; Mette Bohl; Anne Grethe Schioldan
Journal:  Drugs       Date:  2016-01       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.